Evidence map›Paper›PMID 39472367›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade.

Jiyun Shi, Hannan Gao, Yue Wu, Chuangwei Luo, Guangjie Yang, Qi Luo, Bing Jia, Chuanhui Han, Zhaofei Liu, Fan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. The wings of progress: technological and radiopharmaceutical innovations in nuclear medicine.European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiyun Shi *Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Hannan Gao *Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Yue WuMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Chuangwei LuoMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Guangjie YangMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Qi LuoGuangzhou National Laboratory, Guangzhou, 510005, China.
Bing JiaMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Chuanhui HanMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Zhaofei LiuMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
Fan WangMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China. wangfan@bjmu.edu.cn.ORCID 0000-0002-4166-5776

Funding

National Key R&D Program of China 2022YFA1206100National Natural Science Foundation of China (NSFC) projects 92159201 and 81927802Nuclear Energy R&D project HNKF202223(36)
6 · The paper itself

Abstract

purposeIn order to maximize synergistic effect of targeted radionuclide therapy (TRT) and immune checkpoint blockade (ICB) as well as reduce the toxicity, we pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision cancer therapy.

methodsAs a novel targeted radiotherapeutic agent,

results

conclusionWe developed a novel and long-acting radiotherapeutic agent

Indexed as

B7-H1 AntigenGene Expression Regulation, NeoplasticImmune Checkpoint InhibitorsRadioisotopesAnimalsCell Line, TumorFemaleHumansLutetiumMiceMolecular Targeted TherapyRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsImaging-guided therapyImmunotherapyPrecision treatmentSynergistic effectTargeted radionuclide therapy

Identifiers

PMID39472367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.